C-A1SWViscient Bio
3D tissue models, multi-omics, drug discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-A1SW
C-A1SWC-A1SW3D tissue models, multi-omics, drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Seminar summary: https://foresight.org/summary/patient-trials-in-a-dish-paths-forward-david-gobel-methuselah-keith-murphy-organovo/ Program & apply to join: https://foresight.org/biotech-health-extension-program/ Foresight Biotech & Health Extension Meeting sponsored by 100 Plus Capital David Gobel, Methuselah Keith Murphy, Organovo "Patient Trials in a Dish" Paths Forward This session will include a discussion and then ideation on how to efficiently influence events and technology to make "patient trials in a dish" a standard at the FDA more quickly than if might otherwise happen. Keith Murphy will be presenting a state of the tech and regulation followed by Q&A. David Gobel, Methuselah David Gobel is co-founder and Chief Executive Officer of the Methuselah Foundation, a medical charity. To date, Methuselah has given more than $4 million to support research and development in regenerative medicine. With co-founder Aubrey de Grey, Gobel established Methuselah in 2003. Gobel is a
Executive Committee - AGRO Twitter Get Involved Become a Member Contact Us AGRO is a division of ACS Division of American Chemical Society Open mobile menu Close mobile menu Home About Us About Agro Strategic Plan Bylaws Officers & Committees Become a Sponsor Get Involved Friends of Agro Awards Events News Publications PICOGRAM ARCHIVE J Ag Food Chem ACS Books Sponsorship Our Sponsors Become a Sponsor Executive Committee Eden Tesfu Executive Committee (2024-2026) Bayer CropScience St. Louis, MO Send a Message Solito Sumulong Executive Committee (2025-2027) AgriThority Kansas City, Missour
Fish and mussels returned to these rivers after decades of cleanup. But new threats loom | KCUR - Kansas City news and NPR Skip to main content Search Query Show Search World Cup News 2026 elections Local news Missouri news Kansas news Politics Housing & development Education Health Environment & agriculture En Español 2026 elections Local news Missouri news Kansas news Politics Housing & development Education Health Environment & agriculture En Español Arts & Life All arts World Cup 2026 Adventure! Food Sports History Books Local music KC Soundcheck Kansas City guide All a
Sea Turtle, Inc - We are so excited to share another... Facebook Log In Sea Turtle, Inc's Post Sea Turtle, Inc January 22 · Shared with Public We are so excited to share another sponsor for the 2026 Enchantment Under the Sea Gala! Thank you so much LFD Home Furnishing for your support and generosity in becoming a Triton Sponsor! We know you'll help make it a magical evening. Time is running out! Purchase your sponsorship or individual tickets now at seaturtleinc.org/gala . LFD Furniture All reactions: 13 2 shares Like Comment
MASH Summit Speakers | Pharma Experts & Leaders Skip to content Register Before Friday, June 26th & Save Up To $1,000 Day Hour Minute Second September 15-17, 2026 | Boston, MA About About Event Poster Session Events in the Series Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Pre-Conference Day Day One Day Two Why Partner Why Partner Partners Take Part Pricing & Registration Venue & Accommodation Contact Us Full Event Guide Register Now About About Event Poster Session Events in the Series Hanson Wade Products What’s On? Full Event Guide Speakers
%PDF-1.6 %���� 39 0 obj > endobj 83 0 obj >/Filter/FlateDecode/ID[ ]/Index[39 61]/Length 164/Prev 797639/Root 40 0 R/Size 100/Type/XRef/W[1 3 1]>>stream hެб �Q��s�'e�g���� ,"�����K�6�w0XM��!d¦ ߠ�=��X~���N� S�XL$��ҡOnv�f���2���.^�3�_t�n|�Ώ�6q�gz�%W{X����c���s�t>�;�h~�o\b��;m�3�Lwc���={���0��`GC� endstream endobj startxref 0 %%EOF 99 0 obj >stream h�b```�(6�(a`��0p,H��4`�g�d�b��ǰ��#�ag����`y�f�;Z�n�ڝs�����ﶝ��u�`�=�������q@�8�� �Ć`�k��Qy�& ��i7���*s�- fLG� 0^�6Huf�i�NbP��0��{�L� 9 l �1pM`X���������a �� ^N�F����0 e�>T��t�A��4�} �d 0�� ��G ends
--> HOME | Viscient Biosciences top of page Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology HOME ABOUT MANAGEMENT SCIENTIFIC ADVISORS NEWS CAREERS CONTACT More... Use tab to navigate through the menu items. Viscient's Breakthrough Science Shows True Disease READ MORE Viscient is changing the way drugs are developed, using 3D human tissue models to replace the use of outda
Event - Biocom Skip to main content Search Cancel Select Location Choose a location San Diego Greater Los Angeles Bay Area Seattle Sacramento Washington, D.C. Tokyo Enter your location ZIP Code Submit Location Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podcast Episodes About About Us Our Team Board of Directors Careers Contact Our Locations San Diego Greater Los Angel … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Membership Member Benefits Become a Member Conference & Events Funding & Partnering Group Purchasing Policy & Advocacy Workforce Development International Connections Increase Visibility Community Building Catalyst: Innovators Under 40 CEO/Founder Network Converge … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podc
Press releases - Sprint Bioscience Careers Articles Calendar of events Videos Contact us en sv en What we do Introduction Business model Research & development External cooperation Pipeline Internal programs Partner programs Press releases Investors Introduction Corporate governance Corporate governance report Election Committee The share and shareholders Financial calendar Financial reports General Meetings of Shareholders Share Issues About us Navigation What we do Introduction Business model Research & development External cooperation Pipeline Internal programs Partner programs Pres
Thynk Capital Portfolio - Growing Companies to Accelerate Technology Company About Portfolio News Contact A portfolio built on leading-edge innovation. --> Portfolio Companies IMX Health is the first financial futures exchange for the healthcare industry. IMX Health will create a transparent, two sided market for pricing of healthcare assets, will provide hedging opportunities for payers and providers and other healthcare market participants and benefit patients through competition for services and through cushioning price shocks in the marketplace, leading to lower prices and premiums. " data … /theragene-pharmaceuticals/" > More Info Website Agebraix Data has developed an application that will make cloud computing faster and more affordable. Algebraix, through its patented math based technology is focused on Query Acceleration for Big Data. By making queries go orders of magnitude faster it dramatically lowers the cost of cloud computing. " data-website-link="http://www.algebraixdata.com" data-permalink="https://thynkcapital.com/portfolio/agebraix-data/" > More Inf
Smithers | Contract Pharma Continue to Contract Pharma Magazine Latest Issues Latest Issues Explore recent issues of Contract Pharma covering key industry trends. View all Digital Edition Digital Edition Read the full digital version of our magazine online. View all CEO Profiles CEO Profiles Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks. View all Subscribe Now Subscribe Now Stay informed! Subscribe to Contract Pharma for industry
Viscient Bio Inc - Contact information for H1B visa and greencard sponsorship applications "> Welcome, Guest Login Register for Free! Immihelp Welcome, Guest Login Register for Free! Home Greencard Visas Insurance Experiences Forum Tracker USA Travel NRI Tools Blog Select Language For visitors, travel, student and other international travel medical insurance. Visit insubuy.com or call +1 (866) INSUBUY or +1 (972) 985-4400 Home » VISCIENT BIO INC » Contacts Print Share Facebook X LinkedIn WhatsApp Email Share on Facebook X LinkedIn WhatsApp Email Employer Explore more Home - H1B Sponsors … nce 2008. Address 3550 GENERAL ATOMICS CT STE 2-150, SAN DIEGO, CA 92121-1122 1 Application Phone Number (310) 729-9053 Email Address kemurph#*#viscientbio.com Disclaimer: The H1B Sponsors Employers Search tool is intended for informational purposes only. immihelp®.com does not claim any affiliation nor endorsement relationship with any company appearing in the H1B Sponsors Employers Search tool. Insurance Close This website uses cookies, some of which are essential for the f
Methuselah Fund | Springfield Private Equity | Altss For Asset Classes Solutions Compare Case Studies Blog Book a demo Home Private Equity Methuselah Fund Private Equity Updated: Jun 3, 2026 Methuselah Fund Methuselah Fund is a private equity firm based in Springfield, US. It focuses on venture capital investments. The firm has a small team of two staff, including... Methuselah Fund Methuselah Fund is a private equity firm based in Springfield, US. It focuses on venture capital investments. The firm has a small team of two staff, including two investment professionals. Website www.methuselahfu … ionals. Website www.methuselahfund.com LinkedIn linkedin.com/company/methuselah-fund Overview Investment focus Team Deals Network General information Firm type Private Equity Year founded 2016 AUM Undisclosed Location Region North America Country United States City Springfield Corporate office Springfield, United States Principals CEO CEO (Founder of Methuselah Foundation) Managing Director Managing Director Sector focus Biotech & Life Sciences Digital Health Frequently a … l Health Frequently asked questions Who runs investment decisions at Methuselah Fund? The CEO, who also founded the Methuselah Foundation, and the Managing Director lead the investment process, supported by a deep bench of executive and scientific advisors from the longevity field. Specific deal-level authority is not publicly detailed. The firm's website does not name its leadership beyond their functional roles — CEO and Managing Director — omitting individuals' f … Managing Director — omitting individuals' full names. How does Methuselah Fund source its deal flow? Deal flow comes almost entirely through the network of the Methuselah Foundation, a nonprofit the CEO launched 16 years prior to the Fund. The Foundation's scientific collaborators and its defined longevity strategies drive proprietary access to early-stage biopharma and biotech startups. This shared-origin structure means the Fund sees companies before typical vent … s before typical venture firms, often at the translational stage. Is Methuselah Fund a single family office or a venture firm? It is structured as a private equity asset manager, not a single family office. Functionally, it operates as a mission-first venture fund tightly coupled to the Methuselah Foundation. All investments are direct equity sta
SMITHERS-VISCIENT | Business Wire Forside Modtag pressemeddelelser Kunder Om Via Ritzau Bliv kunde SMITHERS-VISCIENT 25.4.2018 17:44:08 CEST | Business Wire | Press release Share Smithers Viscient Europe Appoints Jane Gray as Senior Manager, Terrestrial Ecotoxicology Smithers Viscient , a global contract research organization (CRO), today announced the appointment of Jane Gray to the position of Senior Manager, Terrestrial Ecotoxicology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180425006181/en/ Gray joins Smithers as a highly … today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every securi … 2026 20:00:00 CEST | Press release Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-g … y to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the
Organovo and Viscient Biosciences Collaborate to Develop --> Accessibility: Skip TopNav Organovo and Viscient Biosciences Collaborate to Develop Custom Research Platform for Studying Liver Disease November 06, 2017 08:05 ET | Source: Organovo, Inc. Organovo, Inc. SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) and Viscient Biosciences (“Viscient”) today announced a collaboration to develop a custom research platform for studying liver disease. The partnership is expected to expand upon Organovo’s current service portfolio for compound scre
%PDF-1.7 %���� 9519 0 obj > endobj 9543 0 obj >/Filter/FlateDecode/ID[ ]/Index[9519 54]/Info 9518 0 R/Length 116/Prev 1627583/Root 9520 0 R/Size 9573/Type/XRef/W[1 3 1]>>stream h�bbd```b``��� �AD2��� �y.X�f2��v �u X/ ���$�ٗ�� Xd �� �x> �f����g����#��� &F��`Y�AM�g���)@� �� endstream endobj startxref 0 %%EOF 9572 0 obj >stream h��T�k[U?���6�d��&Y�m��KSe,%�$�a�9mW���T�J˴d�B��U(��Eߗ����a&8���!��o�tE+���� �* �����s~�� (�0&� l��ِ�����s��ϻ�� yJ3X�.�=� �k$�ڱL���?ȭ��U����@c��,��xz��#�M��jo� -��ռ��x��g�y��� ��mm�O{;NɁ6������l��ː��Х�)��M��Q�7��y��_�S�h���Ӷ��7[��B�ގ … �~'���e3 endstream endobj 350 0 obj >stream Microsoft® Word for Microsoft 365 application/pdf Jordan Beltran VIVOSIM LABS, INC._10K_2025_V1 Microsoft® Word for Microsoft 365 2025-06-05T11:35:40-07:00 2025-11-03T20:55:27-05:00 2025-11-03T20:55:27-05:00 uuid:D37095CA-90DE-40DC-8EE3-AD1206AE67CA uuid:ac84116d-c24a-4736-a11f-1f6ead5058da endstream endobj 351 0 obj >stream H�b``������$��PPTR� ���~����� �� |@���T ��#��� 2 S /`MZ ��QJjq2�����%@q� [$)�.��C����&
Thynk Capital, LLC.: The Early Stage Founder's Guide Superscout Programs App Investors More Browse Opportunities VC Programs Index VC Fellowship Programs VC Scout Programs Become a Scout Apply Superscout App Browse By City Browse By University Browse By Accelerator In-Depth Venture Partner Deal memo Resources Scouts Home Learning Center Glossary Frequently Asked Questions Investors Investors Home Add Your Program Dealflow Hub Knowledge Hub Contact Us Articles VC Scout Programs: All You Need to Know From Scout to VC Partner: How Scouting Became the Fastest Track Into Venture Why Scout Pr … w to Navigate Them Become a Scout Browse Opportunities VC Programs Index VC Fellowship Programs VC Scout Programs Become a Scout Apply Superscout App Browse By City Browse By University Browse By Accelerator In-Depth Venture Partner Deal memo Resources Scouts Home Learning Center Glossary Frequently Asked Questions Investors Investors Home Add Your Program Dealflow Hub Knowledge Hub Contact Us Articles VC Scout Programs: All You Need to Know From Scout to VC Partner: How … on Browse By University Browse By Accelerator Learning Center VC Podcasts Scout Application Superscout Store Superscout App Learning Resources Scout Community VC Scout FAQ Deal Memo Tool Glossary Invest With Us Partner Resources Add Your Program AI Funding Hub Knowledge Center Case Studies Contact Us In-Depth Guides Head of Investor Relations Venture Capital Fellow VC Head of Talent VC Head of Platform VC Operating Partner Syndicate Lead VC Principal Angel Investor VC Analyst … geCase Capital Partners Chroma Ventures Inspiration Ventures SMAPE Capital Guul Fund Newline Ventures, LLC Taisu Ventures Kinara Indonesia GulfX Capital Recall Capital ArFintech The Moon Venture Venturade Explore Programs Venture Capital Programs VC Fellowship Programs VC Scout Programs Other Privacy Policy Terms of Service Investor Benefits Grow Your Venture Capital Contacts Find More Liquidity for Your Deals Only Pay When You Win Invest in Trends Faster Get Better Terms Exp … g Space Organizers Startup Podcasters Engineering Candidates VC Scouts With Own Fund Venture Capital Associates Alternative Accelerator Leads Incubators & Accelerators Successful Founders PHD and Postgrad Candidates MBA Candidates Technology Transfer Program Managers Signup to Newsletter Superscout Superscout is a global network of scouts con
Vaidehi Joshi | The Organ Donation and Transplantation Alliance Login Menu Learning Programs & Collaborative Events Advancement Series Tue, Jun 30, 2:00pm Innovations in Advanced Organ Preservation: Next-Gen Kidney Perfusion Tue, Aug 11, 2:00pm Electronic Referrals: The Good, The Bad and the Ugly Thu, Aug 13, 2:00pm Heart Transplant Innovation: Expanding What’s Possible Upcoming On-Demand Conversation Series Tue, Jul 28, 2:00pm Closing Gaps: Understanding Belief Systems Beyond Widely Practiced Religions (Part I) Tue, Aug 4, 2:00pm Transplant Payer Collaborative Program – Topic: TBA Tue, … (ORS) All Jobs Continuing Education Credits Many of our learning opportunities award continuing education credits for the healthcare community of practice. More Details 2026 40 Under 40 Nominations Learn More Resources & Insights Educational Guides Terminology & Data References DCD Educational Guide Community Hospital Resource Guide Transplant Resource Guide Insights The Quality Corner Hospital Executive Insights Transplant Executive Insights Spotlight One-Pagers Il
Yes, we will increase our lifespan - by Elle Griffin Subscribe Sign in Yes, we will increase our lifespan An interview with David Gobel, founder of The Methuselah Foundation. Elle Griffin Oct 10, 2022 35 28 Share Illustration created using Midjourney The Methuselah Foundation is a funding entity for health and longevity research that plans to “make 90 the new 50 by 2030,” and there are several ways they plan on accomplishing this. Funded by their first venture, the 3D bioprinting company Organovo which went public in 2012, the companies in the organization’s portfolio aim to cure cancers, decr … ehicle? We did that in 2007—that’s when we incorporated Methuselah Life Science Fund . Then in 2009, we invested in a company called Organovo, which is now a public company. The thesis of the for-profit is we would invest in mission driven companies, companies that would help accomplish our mission. Then, when they went public or had a liquidity event, we would be able to sell our stock and return that to the Foundation, which would then start more companies and issue more gr
Methuselah Fund Home ABOUT US STRATEGY VENTURES TEAM CONTACT Welcome Investors Home ABOUT US STRATEGY VENTURES TEAM CONTACT Welcome Investors LIFE'S A MIRACLE Normal 0 false false false EN-US JA X-NONE More is Better Our mission: making 90 the new 50 by 2030 MISSION CAPITAL THE NEXT VENTURE CAPITAL The Methuselah Funds, LLC (M Fund) is designed to accelerate results in the longevity field, extending the healthy human lifespan. Our success is measured by financial return on investments and furthering the mission, with the mission being the priority. Our D … Oisín Biotechnologies, former CEO and Founder of Immusoft. Mentor for the Thiel Fellowship. Gary Hudson Strategic Advisor CEO and Co-founder of Oisín Biotechnologies. Serial Entrepreneur, Investor and Philanthropist. Inducted into the International Space Hall of Fame. Ely Kahn Investment Advisor COO and Co-founder of Sqrrl Data, Inc. Former Managing Director at Wharton Venture Partners. Former Director of Cyber-Security Policy at the White House. Aubrey de Grey Scienti … o Scientific Advisor Science Literature Analyst for Methuselah Foundation and M Fund, Former Biochemical Researcher at SENS, Academic. Contact Us Normal 0 false false false EN-US JA X-NONE Please enter your email to receive additional information on our company. Back To Top Copyright © 2022 Methuselah Fund • All rights reserved • Legal Disclaimer • Privacy Policy Legal Disclaimer The sole purpose of this website (“Website”) is to provide information regard … ion regarding the potential financing capabilities of Methuselah Funds, LLC (“M Fund”) for prospective portfolio companies and for individuals considering possible employment with our firm. The information provided on this website, including information regarding current and historical portfolio companies, is not intended to recommend any company or investment described herein. No material on this website shall be used or considered as an offer to sell or a solicitation of an … sell or a solicitation of any offer to buy the securities or services of the M Fund or any other issuer. Offers can only be made where lawful under, and in compliance with, applicable law. This website may not identify all current or prior M Fund portfolio companies for confidentiality or other reasons. The M Fund provides investment advisory se
Harmonix Fund | Portfolio, Investments & AUM | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Investors Harmonix Fund Harmonix Fund La Quinta, California harmonixfund.com Overview Harmonix is a venture capital firm that invests in healthcare, information technology, materials, resources, life sciences, artificial intelligence, machine learning, oncology, manufacturing, and technology-based sectors . The fund focuses on exceptional entrepreneurs and innovative healthcare, life sciences, and deep tech companies … rends and funding raised over time. Unlock full analytics FAQ Where is Harmonix Fund based? When was Harmonix Fund founded? How many portfolio companies does Harmonix Fund have? What are some companies in Harmonix Fund's portfolio? What was Harmonix Fund's most recent investment? What sectors does Harmonix Fund focus on? What company stages does Harmonix Fund focus on? What is Harmonix Fund's AUM? Firmographic Details Headquarters La Quinta, California Year Fou
Viscient Licensing You need to enable JavaScript to run this app.
An Update from the Methuselah Foundation on Progress at Methuselah Fund Portfolio Companies – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to h … ch 2nd, 2020 An Update from the Methuselah Foundation on Progress at Methuselah Fund Portfolio Companies Permalink (With Comments) Permalink (No Comments) Posted by Reason Read 4 Comments Add a Comment The Methuselah Foundation is one of the oldest of the present generation of organizations focused on advancing human rejuvenation, founded more than 15 years ago. At that time there was none of the present enthusiasm for treating aging as a medical condition, and indeed the con … re involved in funding companies and promoting their efforts via the Methuselah Fund. At the present time, this is one of the best uses for philanthropic funding - to help seed a much greater flow of capital into the longevity industry, to enable the first companies to thrive and demonstrate the efficacy of their approaches. (The other best use being, of course, to push forward the numerous promising rejuvenation research projects that continue to languish in academia for lac … ving in my in-box a few days ago, covers some of the highlights from Methuselah Fund portfolio companies. Methuselah Fund has found success by investing in the longevity field when almost no one else was willing to take the risk. The M Fund has proved to be an invaluable resource in our efforts to put mission first and money second. M Fund continues to perform well and plans for a second Fund are currently underway. The Methuselah Fund hopes to continue to guide investments i … nting methods, making them a leading competitor for the NASA Tissue Engineering Prize . In September 2019, the Vascular Tissue Challenge, managed by the Methuselah Foundation for NASA, entered its final phase of the project. By the end of September 2019, a total of 21 teams successfully completed their trial applications after the last Vascular T
Viscient Biosciences Announces First Drug Discovered in 3D Bioprinted Models Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Mult … n of human tissue models with accurate disease relevance, and demonstrating the application of these models to drug development at every stage. About Viscient Biosciences Viscient Biosciences is an early-stage biotechnology company that is developing novel therapies for NASH and other liver diseases. Its lead compound, built to a novel target discovered in proprietary 3D models of human liver disease, is expected to enter the clinic in 2024. Viscient's 3D mo … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Organovo and Viscient Biosciences Collaborate to Develop --> Accessibility: Skip TopNav Organovo and Viscient Biosciences Collaborate to Develop Custom Research Platform for Studying Liver Disease November 06, 2017 08:05 ET | Source: Organovo, Inc. Organovo, Inc. SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) and Viscient Biosciences (“Viscient”) today announced a collaboration to develop a custom research platform for studying liver disease. The partnership is expected to expand upon Organovo’s current service portfolio for compound scre
Organovo & Viscient Biosciences Collaborate to Develop Custom Research Platform You are using an outdated browser. Please upgrade your browser to improve your experience. SUBMISSION GUIDELINES ABOUT US BACK ISSUES MEDIA PLANNER CONTACT FREE PRINT SUBSCRIPTION Login --> --> Subscriptions Current/Back Issues/eBooks Market News & Trends Executive Interviews --> Select a Section Analytical Testing Bioavailability & Solubility Bio Platforms Drug Delivery Injection Devices Excipients Formulation Development Contract Services Market News & Trends Organovo & Viscient Biosciences … Late Stage Customization PCI’s Paul Smallman and Michelle D’Angelo explore the application and opportunities for leveraging advanced technologies in late stage customization and its potential to benefit pharmaceutical and biotech companies in gaining competitive advantage in their global supply chain. Learn More > A Guide to Aseptic Manufacturing The aseptic manufacturing process is complex with each drug candidate's unique set of challenges. Speed to market is necessary, … by WalkerTek . Don’t miss out on this exclusive content! Fill out the form and submit today Fill out the form below to access this exclusive content. --> Close this module
Viscient Biosciences Announces First Drug Discovered In 3D Bioprinted Models Get more Drug Discovery insight with our FREE newsletter sign me up Log In or Subscribe Topics Bioinformatics Regulatory Target Research Innovation Preclinical Entrepreneurship Partners & Suppliers Research Partners Cellular Models Target Discovery Assay & Screening Imaging & Translational Models Analytical Characterization Watch Now Drug Discovery Online Live News | May 2, 2023 Viscient Biosciences Announces First Drug Discovered In 3D Bioprinted Models Company's NASH Drug Expected to Enter Clinic in … n of human tissue models with accurate disease relevance, and demonstrating the application of these models to drug development at every stage. About Viscient Biosciences Viscient Biosciences is an early-stage biotechnology company that is developing novel therapies for NASH and other liver diseases. Its lead compound, built to a novel target discovered in proprietary 3D models of human liver disease, is expected to enter the clinic in 2024. Viscient's 3D models of NASH h
10-K/A FY True 0001497253 0001497253 2025-06-01 0001497253 2024-04-01 2025-03-31 0001497253 2023-09-30 xbrli:shares iso4217:USD   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 10-K/A (Amendment No. 1)   (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31 , 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File No. 001-35996   VIVOSIM LABS, INC. (Exact name o … eding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐   Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “accelerated filer”, “large accelerated filer”, “smaller reporting company” and “emerging growth compa … rd since September 2020. He has served as Chief Executive Officer of Methuselah Fund LLC since December 2016 and as Chief Executive Officer of Methuselah Foundation since September 2001, promoting increasing the healthy human lifespan by various means including: performance prizes, targeted grant making, education, and the creation/funding of biotech startups. Mr. Gobel became Chief Venture Strategist at Transportation Security Administration from January 2009 until March 201 … ences and technology industries. Ms. Milhous was previously an audit partner at Grant Thornton LLP from August 2015 through September 2019 and held various positions with increasing responsibility at Grant Thornton from June 2002 as an audit associate through July 2015 as an audit senior manager. She began her career in June 2000 at Arthur Andersen LLP. Ms. Milhous served on the membership committee of Athena San Diego, a professional women’s leadership organization wit … stockholders, with approximately 92% of stockholder votes cast in favor of the proposal.   During Fiscal 2025, our Executive Chairman, former Chief Financial Officer, and Chief Financial Officer maintained significant stockholder engagement efforts to monitor how our investors vote, obtain their views on key corporate governance and disclos
--> CAREERS | Viscient Biosciences top of page Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology HOME ABOUT MANAGEMENT SCIENTIFIC ADVISORS NEWS CAREERS CONTACT More... Use tab to navigate through the menu items. Careers Apply Now Fraud Alert! Viscient Bio has been alerted to the fact that one or more scammers are claiming to be offering jobs from Viscient Bio. If you ge … ght of external studies Prepare and solubilize compounds for testing Develop or apply expertise in primary cell culture, bioprinting and spheroid culture SKILL AND KNOWLEDGE REQUIREMENTS: Cell culture experience required (experience with primary cells, co-culture systems and/or 3D cell culture models preferred) Hands-on experience with a broad range of gene and protein expression techniques desired (ELISA/MSD, qRT-PCR, NGS, IHC) Experience with high-throughput screenin
%PDF-1.5 %���� 1803 0 obj > endobj 1838 0 obj >/Filter/FlateDecode/ID[ ]/Index[1803 79]/Info 1802 0 R/Length 159/Prev 23314858/Root 1804 0 R/Size 1882/Type/XRef/W[1 3 1]>>stream h�bbd```b`�[ "�@$S �d����vI�Ϧ ��g �y#���b�� "��Hgw�.�(�^O ��q�vz69LF�H� `v>�4���V{�����;�� �d/�=��10)&3��C��@0�"U ��@702���eF ���w�u�^� endstream endobj startxref 0 %%EOF 1881 0 obj >stream h��X{XSG?��A�AQ6hy�lA��b�F��B�BE$ �h�WE6t���VT�*�Q �3 �?eL��䊕@ f-����� �`Lb>���ҳ�WTo ��R�@; ��@�#c0Z �e0� ��� ct ��IЋ� 0�� ;���K@_�%@Z &�`V 3����J;\lCLq� ;�D� �}���-��0� E�@�"�� … �H�f*4F�������*��^�A���.�� ��[d� &m��u�9�0�U�����U � "iEЊS�q����� >stream application/pdf Print 2015-06-29T08:50:34-04:00 2015-06-29T08:50:34-04:00 2015-06-29T08:44:03-04:00 Adobe Illustrator CC 2015 (Macintosh) uuid:22576847-c584-6c43-9b87-1f04690ac920 xmp.did:b8d47fcc-2a4f-4c19-a1fa-65f869859c68 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:beb1fa37-74ad-0349-9ff1-e0104dddcb6d xmp.did:fae3830b-e4ba-45bc-89b4-8f15ea5d3073 uuid:5D20892493BFDB11914A8590D31508C8 pr … 63.671875 73.828125 Adobe PDF library 10.01 endstream endobj 1824 0 obj >stream application/pdf SOTAM16Logo-v1 2015-06-22T15:10:13-04:00 2015-06-22T15:10:13-04:00 2015-06-22T15:09:36-04:00 Adobe Illustrator CC 2015 (Macintosh) uuid:31e60212-661e-f148-89ef-4f41b861f012 xmp.did:2a0b489d-dd54-4817-b5f7-cf761e09dc91 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:1b3d357f-a72d-1540-98de-bb6a5d6b95f6 xmp.did:9e7d56f0-ad25-4378-860e-22aa931e535e uuid:5D20892493BFDB11914A8590D3 … �Ȭ(i p ��4�� ���]k�eF����NR��6�2 �5�,J�Q ! A�l؋:^#D�5���OuH�D�7`�λ\�r!X^[B�rFP���)oJ�`�w����}�E� 2����r��Ѻ��s��bB ӆ{$� �R� �%�h�:c˯z>ٵ��� ��P���^���xF��c��Ubt`D�>Tp��d�&�,�~�0�t:EQ��ևq �ġ9�5>�t K�iϲ]�hVp},8��[��̮� k`��sOz��BX����:V34�&R����-�A�A����X�h%�b�:�� �r48I�G�*�:��� H�j�f! �K5�)�G�V v�ބn {��k ʲ�>ו�Zd����U�vG@��{xH��H�K�����)��X Ms⤵��90��t@u��(K�\舓����A>ɞ��u� ������$]�r����� �# ��p���� e�%.$Q�O h��{�\t� ��uJ�ty� … 9f adobe:docid:indd:d5209669-a7eb-11e0-80f7-9f26c98ca623 default converted from application/x-indesign to application/pdf Adobe InDesign CC 2015 (Windows) / 2016-01-20T15:01:54-05:00 application/pdf Adobe PDF Library 15.0 False endstream endobj 9 0 obj >stream jP � ftypjp2 jp2 jpxbjpx rreq���@ --jp2hihdrcolr�jp2c�O�Q/
Taiwan - Biotech Companies - Careers Page About Directory Promoted Listings Purchase Data Drug Pipelines Data Licensing Weekly Update Newsletter Contact Taiwan - Biotech Companies - Career Pages Armetheon , Merged with Espero Pharma, Mar 2017 Pain Therapeutics , Renamed Cassava Sciences, Mar 2019 SSI Diagnostica Hillerød, Denmark Diagnostics Oakrum Pharma , Website down Aug 2024; Chapter 11 Bankruptcy May 2023 TG ImmunoPharma , Website down Dec 2024 - May 2025 Sterling Pharma Solutions Deeside, UK Contract Development & Manufacturing - APIs , Acquired … Renamed NXI Therapeutics Corinth MedTech , Website down Sep 2023; Did not submit annual report in 2022 or 2023 Eidogen-Sertanty Oceanside, CA Drug Discovery Software TearClear , Website down Dec 2024 - Jun 2025; Seem to be in FL also - not registered in MA or FL OncoFusion , Website gone Jan 2020, no employees on LinkedIn FSG Bio , Changed name to Gossamer Bio, Dec 2017 Shanghai, China BioDuro | fully integrated CRDMO | 28 years. We can ta … p;P10 BIOSCIENCES , Believed defunct, Never registered as MA business, had SBIR grant RedHill Biopharma Tel Aviv, Israel Orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including cancer CytoVera , Gone June 2017 AFFiRiS Vienna, Austria Therapeutic Vaccines Promab Biotechnologies Richmond, CA Services and products in mRNA-LNP, CAR-T/CAR-NK, antibody & bispecific antibody, proteins & cytokines, n … ore Biopharma Oct 2014 Surface Bioadvances , Website Gone, Aug 2016; SBIR grant Anchiano Therapeutics , Merged with Chemomab, Mar 2021; fka BioCanCell; discontinued failed phase 2 gene therapy product to focus on small molecule pipeline Nov 2019 Sunny BioDiscovery , Technically active Sep 2019, but website looks like it was pieced together as a Frankenstein website. Arsia Therapeutics , Bought by Eagle Pharmaceuticals, Nov 2016, $30M + $48M milestones … Devices Santa Ana, CA POC Molecular Diagnostics Evas Therapeutics , SBIR grant. No info Jun 2015. Google says closed Aug 2019 GigaGen San Carlos, CA Immune therapeutics Harvard Apparatus Regenerative Technology Holliston, MA Regenerative Medicine Research Products CymoGen Dx , Acquired by Biocare Medical, Mar 2015 U
A new 3D bioprinted model offers a novel tool to study common liver disease, and perhaps find an effective treatment - Sanford Burnham Prebys Skip to content 0% --> Sanford Burnham Prebys Primary Menu Research Research Overview Disease-Focused Centers Research Disease-Focused Centers NCI-Designated Cancer Center Research NCI-Designated Cancer Center Overview Shared Resources Community Advisory Board Collaborations Leadership Training Events Center for Cardiovascular and Muscular Diseases Center for Neurologic Diseases Center for Metabolic and Liver Diseases Enabling Technology Centers Research … g Opportunities Ways to Give Create a Legacy Donate Now Contact Us You can help fund the next breakthrough Creating a better world with your support. About About Overview Leadership About Leadership Management Scientific Administrative Board of Directors Officers Scientific Advisory Board Careers About Careers Overview Current Openings Benefits Culture and Values Life in Our City Our History Our Community Media Resources Publications Donate Dedicated to human disease and adva
Viscient Biosciences presents new IDO-2 inhibitors | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-ene
Viscient Biosciences Careers, Perks + Culture | Built In Companies Jobs Articles Can't find your company? Create a company profile. View All Jobs Join Log In For Employers Companies Viscient Biosciences Teams Viscient Biosciences Save Saved San Diego 8 Total Employees View Website Overview Jobs Offices Is This Your Company? Claim Profile Biotech Viscient Biosciences is a biotechnology company working at the intersection of human 3D tissue technology and multi-omics analysis. Viscient Biosciences Offices OnSite Workspace Employees work from physical offices. Typical time on-site: San Diego
Methuselah Foundation Methuselah Foundation Home Who We Are Our Team Our Investments Our Partners What We Do Return On Mission About Us Strategies Our Achievements Media Articles Financials Join Us Donate The 300 Monument Volunteer NEWS Home / Who We Are / Our Team Our Investments Our Partners What We Do / Return On Mission About Us Strategies Our Achievements Media Articles Financials Join Us / Donate The 300 Monument Volunteer NEWS / Making 90 the new 50 by 2030 MAKING 90 THE NEW 50 BY 2030 Home / Who We Are / Our Team Our Investments Our Partners What We Do / Return On Mission About Us Stra … 00 Monument Volunteer NEWS / We incubate and sponsor mission-relevant ventures, fund research, and support projects and prizes to accelerate breakthroughs in longevity. Donate Featured News NEWS October 26, 2023 The Evolving Landscape with Turn Biotechnologies October 26, 2023 In the ever-evolving realm of biotechnology, cellular rejuvenation remains one of the most captivating areas of exploration. Read more → October 26, 2023 August 14, 2023 The Revolutionary Potentia
How 3D human tissue models are transforming drug discovery | Article | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques … s require disease induction, either genetic or surgical modifications, diet, or application of a disease inducing agent or toxin, yet this is nothing like how diseases progress in humans, which typically take years to develop. Furthermore, there are genetic differences in animals compared to humans; for example, there is a 15 percent difference in mouse and human protein coding sequences, and, when multiplied by 140,000 genes, this creates vast differences. Another important … ional Strategies 2025-10-08T14:00:00 Sponsored by Eurofins Discovery Whitepaper Application note: Colony morphology matters 2023-02-09T10:49:59 Sponsored by Bio-Techne Article One sample. One shot. The pressure on sample preparation in drug discovery 2026-05-12T09:31:00 Contributor Sugish Pillai , Axel Ziemke and Dr Gary Kusdian Load more Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Business Advertising & Editorial Adv
%PDF-1.7 %���� 676 0 obj > endobj 677 0 obj >/Length 40 /Root 678 0 R /Info 673 0 R /ID[ ]>>stream x�cbd``d``R � 4� J�@h.�+��k�} endstream endobj startxref 0 %%EOF 682 0 obj >stream x�c`�0�3p�d{@ >/OCProperties 672 0 R /Type/Catalog/Metadata 285 0 R >> endobj 679 0 obj >>>/MediaBox[ 0 0 612 792]/Contents 681 0 R /Parent 483 0 R /Type/Page>> endobj 680 0 obj >stream 0 � �.$.$b�������7��:Ȇ?, �.Kh�c�y�RQ(� ���5L������E��B � ��@v���~t�L�6x�u� mK��D��A�����r7B��\�i���5e�8:�K���`��a��"j���nT3���Z,�S��3^�F����[N�) �_�"i3(�}$�e��zm� ��V�Y��n�U��/l%��v�� ���a�6�� … G=Ί}�x/Y81Y%ĵo68� �Cv��ad��Ej >��* �v7��� S��.b���ec�J�"/@#�Y � ���,�rfpvm'uդ���L-h��h�h�x�u�� DZOB��Q�od.�}�+�c�iA�)�m���e�4�p��Lmn?�Չ��yp0���e�� ��z���yN��K�ط�P䷷z�� ��Y �+� �ek�Ρ����:�j��w�o�/��E��BZ?�=� {���ބ�nuǓ� ����L� ���H4L~� J厞 K�ffA�+ �csVY�ɭW�K�[���ʓF _���J��u�xp��M#�b \���6.G8&�,(b� B�Cyi��S.^~�x�{��T@ ��*��D��8�&(Q��c��a�W�5SCڷ����i( �Ȣ뾏�&���� �5.�|��A!ϖ�)�#� �:/���=c���Q�*�� D��� Ī=�qT]~&@۸⨶H� ��xA�hx�,5��q� … 8.2.12.24 2022-05-27T17:16:09-04:00 2022-05-27T17:16:09-04:00 Foxit FXPDFA 1.2 application/pdf endstream endobj 286 0 obj >stream x��\]s�6�+xk�Ј�$���"ˉw �ki�����j1�fe�#�i�����\����v � �{���\�q�0� &�C2C ��)> K��gʬ���$��ECk�l�8W ��c�:��\��b\k��Ѱ��a C�����Y�S��,$�L�WY��X�,:$(��"p��R��`t���y)�KWdGr��� �I�9�R?���ؚ��x��T4:P���-����h�o�`h0N��d2�:ӆ �ht�I`d�1�f��e&#��� �������4����h�x3I�DI%��,MFxYJ$ҸH ��RC �$M�8�.�,�;�9#;�1^MSK���YA���m`������97�,K�6,S�
%PDF-1.3 %��������� 4 0 obj > stream x�]�v�Ƒ���hs�á4 �:�0bb�r 'v����shjbq���ry���g����W]t� E*VB��Fwuݫ�������� �����p�|6�M�l�7K��]�g/n3wv��ɬ�%�w�%�g�H') ^d�E�.]5�O�R�ڮf�I9w�ݚo�_= syQ��rL�/ݳ��l��� �Ս�]^./�_��;���p�VC��B���Y�M'�t^Đ5�qO�����Ifp$ � 9�ܬ��Cyʀ��s0^��F/��� zl�M8�k�d���G��d(� ��) rW3���>je�z+P���7��h7�xڭ�C����.f�R����;5@^�%Ps�����`�;C���� ���|��/�9�!���Kh7ܾ���F?�?��DxyHɺ6�\��������ـ�E"Yo�*�\2��IcS�A�MI6K����$˓KW�8�&̺4��d1�&w�&Y��+, �f !��Lh����ꑓ�, m=k��;"�z�k��J�HUY��ޚν�&ե�r~�����]C�}�\ޢ ����c(����� r�-� c�u��nnnD���!} ���C�,X���'�R�0?
%PDF-1.5 %���� 2469 0 obj > endobj xref 2469 127 0000000016 00000 n 0000010101 00000 n 0000010218 00000 n 0000011081 00000 n 0000011341 00000 n 0000011901 00000 n 0000012405 00000 n 0000012667 00000 n 0000013291 00000 n 0000013813 00000 n 0000013901 00000 n 0000014016 00000 n 0000014141 00000 n 0000014190 00000 n 0000014229 00000 n 0000014398 00000 n 0000014653 00000 n 0000015136 00000 n 0000015577 00000 n 0000016112 00000 n 0000016627 00000 n 0000017192 00000 n 0000017317 00000 n 0000017442 00000 n 0000020991 00000 n 0000021526 00000 n 0000021555 00000 n 0000021841 00000 n 0000022096 00000 n … �a]��3Kdx��I�(i�pߓ��@+��"�;�� ?z�,�ԯ�إY endstream endobj 2569 0 obj >stream application/pdf Print 2015-02-18T07:31:56-05:00 2015-02-18T07:31:56-05:00 2010-12-15T12:52:55-05:00 Adobe Illustrator CS4 uuid:5d461cb3-02d7-f04e-b536-da3737e177aa xmp.did:2E30B98EA22168118570F84B921CAF00 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:25309aba-6ddf-a941-9bd2-dd7653570218 xmp.did:F77F117407206811818C85DF6A1A75C3 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf converted from a … 099C3B601C4548 2008-04-17T14:19:15+05:30 Adobe Illustrator CS4 / converted from application/pdf to <unknown> converted from application/pdf to <unknown> saved xmp.iid:F97F1174072068118D4ED246B3ADB1C6 2008-05-15T16:23:06-07:00 Adobe Illustrator CS4 / saved xmp.iid:FA7F1174072068118D4ED246B3ADB1C6 2008-05-15T17:10:45-07:00 Adobe Illustrator CS4 / saved xmp.iid:EF7F117407206811A46CA4519D24356B 2008-05-15T22:53:33-07:00 Adobe Illustrator CS4 / saved xmp.iid:F07F117407 … DDFD38D0CF24DD 2008-05-16T10:35:43-07:00 Adobe Illustrator CS4 / converted from application/pdf to <unknown> saved xmp.iid:F97F117407206811BDDDFD38D0CF24DD 2008-05-16T10:40:59-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to <unknown> saved xmp.iid:FA7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:26:55-07:00 Adobe Illustrator CS4 / saved xmp.iid:FB7F117407206811BDDDFD38D0CF24DD 2008-05-16T11:29:01-07:00 Adobe Illustrator CS4 / saved … C1BF14D1759E83 2008-05-16T15:52:22-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:FA7F117407206811B628E3BF27C8C41B 2008-05-22T13:28:01-07:00 Adobe Illustrator CS4 / converted from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator saved xmp.iid:
VivoSim Labs Inc (VIVS): $ONVO An Open Letter to Organovo Shareho... Boards: Quotes: Favorites Popular Monitor Movers Level 2 News Menu Breakout Boards Most Read Most Posted Most Followed Members Active Boards New Boards Site Stats Poststream Ticker Buzz Cloud Boards Stocks Commodities Forex Cryptocurrency The Lounge News All Company News iHub Market News News Scanner Price & News Alerts Market Data Monitor Level 2 Live Charts Trades Portfolio Economic Calendar Follow Feed Trader Alerts Price Alerts Markets Crypto Forex Commodities Futures Discover Market Movers Options Flow Breakouts Scanner … ces, Mr. Murphy’s current company, has already crossed a major milestone in the application of bioprinting to NASH drug discovery Viscient incorporates into bioprinting additional cutting edge techniques, including single cell sequencing and bioinformatics tools Major investment funds have expressed support for Viscient’s approach January 07, 2020 08:00 AM Eastern Standard Time https://www.businesswire.com/news/home/20200107005367/en/Open-Letter-Organovo-Shareholders-Organovo … w five-year agreement with the Teamsters Local 237 Welfare and Retirees Benefit Fund, one of the largest Teamsters-affiliated benefit organizations in the United States. The agreement represents another significant milestone for CHS as organizations […] Germany’s Merck to Acquire Bio-Techne in $11.3 Billion Deal Germany’s Merck KGaA has announced a major acquisition agreement to buy U.S.-based life sciences company Bio-Techne Corp (NASDAQ:TECH) in a deal valued at approximate
February 2018 - 3DHeals Blog All Blogs Guides Expert’s Corner Influencer Interviews Events Courses Directory Podcast More FAQ Career Networking ? Live Facebook Group Meetup Media Store About Pitch3D Login Register Blog Events Courses Directory Podcast More All Blogs Guides Expert’s Corner Influencer Interviews FAQ Career Networking Media Store About Pitch3D ? Live Facebook Group Meetup Home February 2018 Interview: Dr. Markus Reiterer, Senior Principle Scientist, Medtronic February 27, 2018 | 1 Comment Markus Reiterer, grew up in Austria and received both his Dipl.-In … regulatory framework exists when the first products are ready for in the human application. Jenny: If you are granted three wishes by a higher being, what would they be? Markus: I would ask to win the lottery to have the funding to create a research center for materials in bio- and environmental engineering applications in a beautiful place. Jenny: What advice would you give to a smart driven college student in the “real world”? What bad advice you heard should they i … work was conducted in virology at Oregon State University with a post-doctoral fellowship at the University of California San Francisco in glucocorticoid gene regulation. He has drug discovery experience in the Inflammation, Oncology, Endocrine and Cardiovascular drug discovery therapeutic areas and his work has led to or enhanced the development of multiple marketed compounds. His target expertise includes Nuclear Receptors, Kinases, and Transporters. He has published … cal translation and complete disease modeling. Solutions: The application and iteration of 3D models, but it will take a lot of work and the climbing of a steep learning curve that we’re just starting to ascend. Jenny: What advice would you give to a smart driven college student in the “real world”? What bad advice you heard should they ignore? Jeff: Good Advice: Ask questions and listen to the answers, then ask another question based on that answer. B … edical school at Vanderbilt University where he also completed his Oral Surgery residency in 2007. This was followed by a Cosmetic surgery fellowship in 2008 at Ohio State alongside Dr. T. William Evans, fine-tuning his skills in the management of the soft-tissue and skin. He is currently a clinical instructor at the Department of Oral Surgery at
%PDF-1.4 %���� 325 0 obj >/Metadata 361 0 R/PageLabels 149 0 R/Pages 151 0 R/StructTreeRoot 157 0 R/Type/Catalog/ViewerPreferences >>> endobj 361 0 obj >stream endstream endobj 149 0 obj > endobj 151 0 obj > endobj 157 0 obj > endobj 158 0 obj >/A2 >/A4 >/A6 >/Pa0 >/Pa4 >/Pa5 >/Pa9 >>> endobj 159 0 obj > endobj 160 0 obj > endobj 161 0 obj > endobj 162 0 obj [323 0 R 283 0 R 317 0 R 318 0 R 319 0 R 284 0 R 284 0 R 284 0 R 284 0 R 320 0 R 284 0 R 321 0 R 284 0 R 284 0 R 285 0 R 285 0 R 285 0 R 285 0 R 316 0 R 285 0 R 285 0 R 285 0 R 285 0 R 285 0 R 285 0 R 285 0 R 285 0 R 285 0 R 285 0 R 285 0 … 11-07-28T12:54:50-04:00 2011-07-28T12:54:50-04:00 2011-07-28T12:54:50-04:00 XPP application/pdf uuid:474c436a-4c05-4571-9efd-6ec3ac19359c uuid:d998511b-b006-46af-972a-4d944cb9b6e5 endstream endobj 141 0 obj > endobj 140 0 obj > endobj 139 0 obj > endobj 138 0 obj > endobj 78 0 obj > endobj 50 0 obj >stream H�|Wmsܸ ���B3�E�xe�zOo���&�����ۦ7�N�+qwK�BQ�l}�zY'��@$�^W�A �� �����:a;?�t}{㬮�k^�����}�c���{|~�?����՛����8�|?p�I� � � %V;�#�����9:8,�a_��A!���HC��dN�BU�S���z … 11-07-28T12:54:50-04:00 2011-07-28T12:54:50-04:00 2011-07-28T12:54:50-04:00 XPP application/pdf uuid:b202f086-afdf-4d3a-aa67-a7230af4fb35 uuid:41eac134-a9e2-488a-a465-a5377995ef80 endstream endobj 137 0 obj > endobj 136 0 obj > endobj 135 0 obj > endobj 134 0 obj > endobj 133 0 obj > endobj 132 0 obj > endobj 131 0 obj > endobj 52 0 obj > endobj 54 0 obj > endobj 55 0 obj >stream H�\���� ��>� �C1�,B�R�a�e��F'��Q1搷�і.������;���z�2��̀&�m�5l� �8;�Z֙���m 'x�K����I���� # … 11-07-28T12:54:50-04:00 2011-07-28T12:54:50-04:00 2011-07-28T12:54:50-04:00 XPP application/pdf uuid:ada0699a-6d5b-4c7e-afb1-67d307eaac3e uuid:c92ff8ae-bae2-4917-9358-930b94442d04 endstream endobj 129 0 obj > endobj 128 0 obj > endobj 127 0 obj > endobj 126 0 obj > endobj 93 0 obj > endobj 41 0 obj >stream H�lW�r�6}�W�)��2i�/S�T { -J �$�Qyٵf0�Q|rxv(���̢���E^Q�d6���8��c갓���گ��~���{IUY~v ��ieX�LE ��:�K����"�t20�,og�vep ��8�jY��������)��8 � H���C�1f�Ό�e �# … 11-07-28T12:54:49-04:00 2011-07-28T12:54:49-04:00 2011-07-28T12:54:49-04:00 XPP application/pdf uuid:129b398e-4f1c-4f4a-ad8c-b73fb6f696f1 uuid:441e695e-ed63-4f0d-a5b2-f925a5a3f1a0 endstream endobj 125 0 obj > endobj 124 0 obj > endobj 123 0 obj > endobj 122 0 obj > endobj 121 0 obj > endobj 42 0 obj > endobj 44 0 obj > endobj 43 0 obj >stream H�b
%PDF-1.4 %äüöß 2 0 obj > stream x��XKo7���9�e� l��7z(zj�A�"�!��$)ǖ��z�~ �; Ό�3�7�.���_ ���ݗ?��_��p���a���b>�T��UF�\Z�f�aM�oښ�^R���� n/��'f�g��V�6��=os������ _o�k}���o/╿ s@��g)� H[����|E'�������_wo�����_(��A�8(��or��ee���SV�� � ��!l� )P�r Y �@�&�, �ˀ"�a�U�"`�@�dE��a$�f�(~�+�ʣu@�J�����` E�K A�G��U@��- FA0��bk�3Yi�'BQ���&*V}�t�L�فH5�if� �Ze�bO�q& ��c��$���d�+�*�o"���4n1ѫ���I��ę��h��u��J_h%RgRf�f�rH@�!ҷ�sW��� H�LR7���"�G@� ��iL�u�!�ݯH��B!b �3�D���HԸ�� �EhU�1����ę�D.����DA3P d]^5Y��AW��Ū:�zQ��QQY��Z DG��M�H���� �^��0`�̻̔^ :�Z��� ϩ���ϩ���ϩ
--> 2016 Floorplan & Exhibitors - BCPC Congress Home About Programme Speakers Delegate Information Register Register Interest Sponsors 2024 Sponsors 2023 Sponsors 2022 Sponsors 2021 Sponsors 2019 Sponsors 2018 Sponsors 2017 Sponsors 2016 Sponsors 2015 Sponsors Out & About News Past Events Contact 2016 Floorplan & Exhibitors Exhibitors List Exhibitor Stand Position Agrow Stand 22 APC (Agchem Project Consulting Ltd) Stand 10 BCPC Stand 14 CEM Analytical Services Limited (CEMAS) Stand 12 Chemex Environmental International Ltd Stand 4 CiToxLAB Stand 26 Covance Stand 3 EBRC Con
Revolutionizing liver disease research with 3D bioprinted model Skip to main content Main navigation Close Back --> --> Home Help & Arrival Contact International Representatives Arrival Hotel & CityInfos FAQ Exhibit Trade Fair Participation Online registration Become an exhibitor Stand Cost Calculator Focus topics Trade fair preparations MEDICA HOSPITAL OF THE FUTURE Information Contact persons Download center At a glance Service ABC Hotel & CityInfos Stand constructor portal Traffic regulations Services Fair Match Online-Order-System (OOS) Exhibitor Profile Exhibitor dashboard Scan2Lead Logos … Press Accreditation Press contact Press releases Exhibit Exhibit Exhibit Online Application Online Order System Marketing Services Exhibitor contact Dashboard Parallel event Parallel event Parallel event COMPAMED About MEDICA About MEDICA About MEDICA Product Categories At a glance Newsletter Spheres of MEDICA-Magazine Contact & Support Write to us Hotline +49 211 / 4560-01 FAQs Digital Services Act (DSA) Legal Imprint Privacy Policy Accessibility Compliance Cookie Settings F
%PDF-1.6 %���� 12951 0 obj > endobj 12969 0 obj >/Filter/FlateDecode/ID[ ]/Index[12951 26]/Info 12950 0 R/Length 94/Prev 743611/Root 12952 0 R/Size 12977/Type/XRef/W[1 3 1]>>stream h�bbd```b``N����d"X� Lv�E��H�X0�L��H�0����$��`v�\`��$��m``bd0R�M�I�g��� ��; endstream endobj startxref 0 %%EOF 12976 0 obj >stream h�b```�� , >/Metadata 250 0 R/PageLayout/OneColumn/Pages 12935 0 R/StructTreeRoot 254 0 R/Type/Catalog>> endobj 12953 0 obj >/Font >/XObject >>>/Rotate 0/StructParents 0/Tabs/S/Type/Page>> endobj 12954 0 obj >stream h��Tmo�0�+�����X�*�e Ct�i �δiR% ��=g� t/�� � �w��� … b9edd7b-72f1-4f7b-8c1c-267a1a32cd25 uuid:0f580f8a-bbae-4319-9b55-053528a3f540 3 application/pdf Nicholas Zuccaro Adobe PDF Library 20.12.80 endstream endobj 251 0 obj >stream hޜԿN1 �W�\��q,U]Y�� 1T�B,�( �=�|N:�����K�)��L�x}�J���J"HF1���Z[bJ�Z��M�JA]"M��Tu��Q�d�-�5A�ŵ���f�ܼ~�|P�����t�� �������}� ����x�nG��s���u=�P�H owx?����^�����"�>� ����{c������2 ������8����S������8���)�t��1i�F��9@e��G"c�|� ��`X�`� @��'uT�`X��4��� h~��_��S|�Uh���飼���k�>
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
--> 2017 Sponsors - BCPC Congress Home About Programme Speakers Delegate Information Register Register Interest Sponsors 2024 Sponsors 2023 Sponsors 2022 Sponsors 2021 Sponsors 2019 Sponsors 2018 Sponsors 2017 Sponsors 2016 Sponsors 2015 Sponsors Out & About News Past Events Contact 2017 Sponsors Headline Sponsor JSC International Limited Headline Sponsor Triskelion B.V. Pre event Drinks Reception Sponsor APC (Agchem Project Consulting Ltd) Event Sponsor CEM Analytical Services Limited (CEMAS) Event Sponsor Citox Event Sponsor EBRC Consulting GmbH Event Sponsor SGS United Kingdom L
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
--> CAREERS | Viscient Biosciences top of page Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology HOME ABOUT MANAGEMENT SCIENTIFIC ADVISORS NEWS CAREERS CONTACT More... Use tab to navigate through the menu items. Careers Apply Now Fraud Alert! Viscient Bio has been alerted to the fact that one or more scammers are claiming to be offering jobs from Viscient Bio. If you ge … ght of external studies Prepare and solubilize compounds for testing Develop or apply expertise in primary cell culture, bioprinting and spheroid culture SKILL AND KNOWLEDGE REQUIREMENTS: Cell culture experience required (experience with primary cells, co-culture systems and/or 3D cell culture models preferred) Hands-on experience with a broad range of gene and protein expression techniques desired (ELISA/MSD, qRT-PCR, NGS, IHC) Experience with high-throughput screenin
The Smithers Group Portfolio Investments, The Smithers Group Funds, The Smithers Group Exits Technology Vendors Recent Research Newsletter Media Support Login Who We Serve Function Corporate Strategy Corporate Venture Capital Venture Capital IT Corporate Innovation How VCs Use CB Insights Go to the video gallery → Industries Consumer & Retail Tech Insurance Healthcare Industrials Financial Services Professional Services Professional Services Learn More → Success Stories How We Help Understand Tech Markets Anticipate Competitor Strategy Determine Tech Strategy Connect with Tech Vendors & … ithers Group BUSINESS PRODUCTS & SERVICES smithers.com Are you an investor? Submit your portfolio details now to be considered in our investor rankings. Submit portfolio details Partners & Customers 1 About The Smithers Group The Smithers Group includes Smithers Pira, Smithers Rapra, Smithers Apex, Smithers Viscient, Smithers Pharma Services, and Smithers Quality Assessments. Each Smithers Group company provides technology-based services focused on a defined market. A … services. Headquarters Location Akron, Ohio, United States Are you an investor? Submit your portfolio details now to be considered in our investor rankings. Submit portfolio details Latest The Smithers Group News World Tire Testing Market Report 2022, Featuring Profiles of Key Players Calspan, The Smithers Group, A&D Technology, TUV SUD and Dufournier Technologies May 26, 2022 The global tire testing market is projected to register growth at a significant rate during the
%PDF-1.6 %���� 412 0 obj > endobj 431 0 obj >/Filter/FlateDecode/ID[ ]/Index[412 32]/Info 411 0 R/Length 99/Prev 1331567/Root 413 0 R/Size 444/Type/XRef/W[1 3 1]>>stream h�bbd```b``���wA$��d�����# �y��i���K�*��d0����$���K�@��@��c��� �`[�v�I�g`L�`�cD endstream endobj startxref 0 %%EOF 443 0 obj >stream h�b```"Nv& a`e`c`a��r$��i��� ˴v��&�}��o�N�gJ ��cJ��`:;A1��m�C��� � �1 _�Vd��A�+�� �3��$��� {������� ���?3�l���8A��x����rGsA&> W��� 9��Z�8�fT�*Y��4�#O�RE�b�#�n�G� ��˸d2��/��/Yg� � ��{,��}r�hT���Ӝ}ئ tj�I���4��tn�N�e|̀(����J�* ���r�w�0� … :8286acbf-be17-11b2-0a00-def0855af8ca uuid:acdee8ae-d5b2-43fe-9031-7b4c62dd8901 application/pdf Adobe PDF Library 18.0.5 endstream endobj 322 0 obj >stream H�b``������$��PPTR� ���~����� �� |@���T ��#��� 2 S /`MZ ��QJjq2�����%@q� [$)�.��C����&��� �^���ʢ��CKKKǔ��T������bϼ������Ē��Z� ��_������`h�J�� P8BX��A�!@riQ�V$�����Pɰ���4c� >stream hޜ�Mk�@��S�RHOڙ���KL�)��ɡB1X�V �|ȿ�X���S���w�ю|M���L!) �ge%qL�9�z��� �*=�����e����K�50�L�8e������;}Ȟ./�
About - Avazyme - Pharma. Food. Agriculture. Skip to content Call Us Today! 919.604.4571 Toggle Navigation HOME CONTACT ABOUT QUALITY SYSTEMS / COMPLIANCE Toggle Navigation SERVICES INDUSTRIES & CUSTOMERS SERVED PFAS PHARMA AGRICULTURE FOOD & BEVERAGES FEED VETERINARY PRODUCTS COSMETICS FORENSIC SCIENCE NEWS TECHNOLOGIES REQUEST A QUOTE About Home » About About admin 2024-01-06T18:57:18+00:00 Avazyme is a Science Company Customer centric culture and empowers all employees to enhance customer experience. From inception we structured ourselves around our customers and their needs
Organovo Holdings Founder Issues Letter Regarding Alternative Paths to Illogical Merger With Tarveda Therapeutics to Stockholders - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Organovo Holdings Founder Issues Letter Regarding Alternative Paths to Illogical Merger With Tarveda Therapeutics to Stockholders March 23, 2020 | 9 min read Twitter LinkedIn Facebook Email Print Believes the Board, Which Has Presided Over Significant Value Destruction in Recent Years, Has Asked … ompany in need of additional capital beyond Organovo’s current cash in order to fund clinical trials to a successful point. In contrast, Organovo’s stock has been a relatively safer harbor, trending with the NASDAQ overall. Considering Organovo has natural downside protection due to being valued near its book value, I believe that waiting—and not consummating a reckless merger—may be the best course until the current storm has passed. I want to stress that my assessment is un … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Explore News Jobs Newslett … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
An Open Letter to Organovo Shareholders: Organovo Founder Sees Continued Success in Bioprinting - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals An Open Letter to Organovo Shareholders: Organovo Founder Sees Continued Success in Bioprinting January 7, 2020 | 4 min read Twitter LinkedIn Facebook Email Print Keith Murphy, founder, former CEO and Chairman Emeritus of Organovo, says bioprinting and similar technologies are going strong and s … ces, Mr. Murphy’s current company, has already crossed a major milestone in the application of bioprinting to NASH drug discovery Viscient incorporates into bioprinting additional cutting edge techniques, including single cell sequencing and bioinformatics tools Major investment funds have expressed support for Viscient’s approach SAN DIEGO--( BUSINESS WIRE )-- Organovo Founder Keith Murphy sent the following letter to company shareholders: At the Organovo annual shareholder … ea, their previous success, which sold to AstraZeneca for $1.25 billion . Major fund investors in Organovo took a look at what Viscient is doing and think it is top rate. The combination of using 3D tissues and single-cell sequencing technologies makes Viscient a leading innovator, and these are investors that put their money to work specifically on groundbreaking innovation. The investors told us that they either were “strong supporters” or that they were “fully supporting” … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Viscient Biosciences Proposes Merger to Unlock 3D Bioprinting Potential in Drug Discovery With Organovo - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Viscient Biosciences Proposes Merger to Unlock 3D Bioprinting Potential in Drug Discovery With Organovo October 2, 2019 | 5 min read Twitter LinkedIn Facebook Email Print Viscient Biosciences (“Viscient”), a biotech therapeutics company working at the intersection of 3D tissue technology and tra … ant unmet medical need, today announced that it has formally submitted a merger proposal to Organovo Holdings, Inc.’s (“Organovo”) Board of Directors to combine the two companies. SAN DIEGO--( BUSINESS WIRE )-- Viscient Biosciences (“Viscient”), a biotech therapeutics company working at the intersection of 3D tissue technology and transcriptomics technology to discover and develop drugs across a range of therapeutic areas with significant unmet medical need, today announced t … ant unmet medical need, today announced that it has formally submitted a merger proposal to Organovo Holdings, Inc.’s (“Organovo”) Board of Directors to combine the two companies. Viscient has previously made strides forward using 3D liver tissue to discover drug opportunities for non-alcoholic steatohepatitis (“NASH”). On August 7, 2019, Organovo announced that it had engaged a financial advisor to assist in the exploration of strategic alternatives after timeline challenges … andidates, unlocking significant value for all stakeholders.” Viscient’s merger proposal involves the issuance of new Organovo shares to existing Viscient shareholders. It is expected that the combined entity could be up to 43% owned by Organovo’s existing shareholders and the balance owned by Viscient’s shareholders. The final ownership allocati
Trailblazing work with 3D Human Liver Models Yields Accurate MASH (formerly NASH) Phenotype - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene The … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Trailblazing work with 3D Human Liver Models Yields Accurate MASH (formerly NASH) Phenotype January 23, 2024 | 5 min read Twitter LinkedIn Facebook Email Print Viscient Biosciences announced that its scientists, along with collaborators from University of California, San Diego, Sanford-Burnham-Prebys medic … 3D human cellular models with high clinical relevance, and in demonstrating the application of these models to impact drug development at every stage. About Viscient Biosciences Viscient Biosciences is an early-stage biotechnology company that is developing novel therapies for MASH and other liver diseases. Its lead compound, built to a novel target discovered in proprietary 3D models of human liver disease, is expected to enter the clinic in the next 12 months. These models … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
WHO WE ARE — Methuselah Foundation Methuselah Foundation Home Who We Are Our Team Our Investments Our Partners What We Do Return On Mission About Us Strategies Our Achievements Media Articles Financials Join Us Donate The 300 Monument Volunteer NEWS Home / Who We Are / Our Team Our Investments Our Partners What We Do / Return On Mission About Us Strategies Our Achievements Media Articles Financials Join Us / Donate The 300 Monument Volunteer NEWS / Making 90 the new 50 by 2030 WHO WE ARE Mission first Home / Who We Are / Our Team Our Investments Our Partners What We Do / Return On Missio … of Turn Biotechnologies and co-founder and managing director of the Methuselah Fund. An entrepreneur, philanthropist, and investor, Ruiz has advised in the development of several mission-aligned biotechnologies, helping them to evolve from academic investigations to commercial enterprises. Scientific Advisors Luis Alvarez, scientific advisor Alvarez is the director of Organ Manufacturing at United Therapeutics, where he is developing a novel bioprinting platform to manufactu … d earliest by Alzheimer’s disease. For more information, click here. METHUSELAH FUND Investment: 2017 The Methuselah Fund – a subsidiary of Methuselah Foundation – invests in mission-critical startups. Its mission focus helps early-stage companies avoid compromising and pivoting away from our longevity mission, which commonly occurs when traditional venture capital funds pressure companies to prematurely achieve financial returns. The fund focuses on potential breakthrough bi … ducted extensive research to enhance human health. We contributed $1 million to fund its development of engineered replacement brain structures. Researchers led by Dr. Jean M. Hérbert, professor of neurosciences and genetics at Einstein, are searching for ways to correct age-related neurological damage by removing the damage and replacing it at the small tissue level without losing memories or self-identity. For more information, click here. ALLIANCE FOR LONGEVITY INITIATIVES … ducational competitions. ICS has supported corporate, government and non-profit prize programs. For more information, click here. ISS NATIONAL LABORATORY The International Space Station (ISS), managed by the Center for the Advancement of Science in Space (CASIS), was designated a U.S. National Laboratory in 2005 by Congress. Its mission is to mak
A Bioprinting World Map - 3DPrint.com | Additive Manufacturing Business Site Sponsor: Log In | Register Data & Research PRO Content Advertise Instant 3D Printing Quote Search --> Site Sponsor: News View All News Data & Analysis --> Bioprinting, Medical and Dental 3D Software 3D Scanning Aerospace Education Metals Materials Editorials/Opinions Exclusive Interviews Podcast 3D Printing News Briefs, June 27, 2026: Nanoscale 3D Printing, Defense Readiness, & More US Army Awards Continuous Composites 3D Printed Missile Component Contract Why Qualification Is Becoming the Next Frontier for AM in … ng the Next Frontier for AM in Energy About / Team Advertise Newsletter Contact/Submit Search Data & Research PRO Content Advertise Instant 3D Printing Quote Log In Register A Bioprinting World Map June 19, 2019 by Vanesa Listek 3D Printing Bioprinting Business Medical 3D Printing Share this Article --> With 119 established bioprinting companies and many entrepreneurs worldwide showing interest in the emerging field, it’s just a matter of time before it becomes one of t … hips continue to emerge among businesses, scientists, and researchers, eager to apply their innovative spirit, knowledge of biological sciences, engineering, mathematics, and other fields that are contributing to the unstoppable evolution of bioprinting, so that it can eventually transition from the research and development phases to the pre-clinical and trial, getting one step closer to changing people’s lives. NORTH AMERICA The US and Canadian bioprinting market inclu
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
S-1 1 ea0283777-s1_vivosim.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on March 27, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VivoSim Labs, Inc. (Exact name of registrant as specified in its charter) Delaware 2836 27-1488943 (State or other jurisdiction of incorporation or organization) &n … , prior to the receipt of any proceeds from this offering, is not sufficient to fund operations beyond July 2026. If we were to receive net proceeds of $3.4 million from this offering, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will meet our capital needs into 2027. If we receive the foregoing net proceeds of $3.4 million in this offering, and if we raise an additional $5.0 million in net proceeds through the sal … eds from this offering. Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section titled “Use of Proceeds.” Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways t … ely increase the value of your investment, and the failure by our management to apply these funds effectively could harm our business. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our common stock price to decline. If you purchase securities in this offering, you will experience immediate and substantial dilution and may experience additional dilution … ing, and we do not expect a market to develop. In addition, we do not intend to apply to list the common warrants or pre-funded warrants on any national securities exchange or other nationally recognized trading system, including the Nasdaq Capital Market. Without an active market, the liquidity of the common warrants and pre-funded warrants will
Viscient Bio discovers first drug using 3D bioprinted tissue model Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Br
Viscient Biosciences Announces First Drug Discovered in 3D Bioprinted Models - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opi … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Viscient Biosciences Announces First Drug Discovered in 3D Bioprinted Models May 2, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Viscient Bio, Inc. (“Viscient”) today announced it has identified the world’s first drug candidate discovered primarily using 3D bioprinted tissue models of disease fo … n of human tissue models with accurate disease relevance, and demonstrating the application of these models to drug development at every stage. About Viscient Biosciences Viscient Biosciences is an early-stage biotechnology company that is developing novel therapies for NASH and other liver diseases. Its lead compound, built to a novel target discovered in proprietary 3D models of human liver disease, is expected to enter the clinic in 2024. Viscient's 3D mo … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Matinas BioPharma Strengthens Board with Two Biotech Veterans | MTNB Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto S … a Managing Director of Third Ridge Capital Management, LLC, a U.S. equity hedge fund. Mr. Neugeboren was also Chief Administrative Officer and Director of Equity Research Operations at Lehman Brothers where he was a senior member of the management team responsible for operations for a 200-person department with direct management of technology, finance, editorial and production, human resources, and compliance. He was Deputy Director of Equity Research at UBS, formerly Warburg
Murphy, Keith - The Wall Street Transcript Toggle navigation Home Experts Reports Products News About Us Series General Investing Financial Services Consumer Industry & Services Natural Resources Healthcare Technology Contact Us Login New Login New Reg --> Keith Murphy Keith Murphy is Founder and Executive Chairman of Organovo Holdings Inc., as well as the CEO and Chairman of Viscient Bio, Inc. He is also a serial entrepreneur and investor in biotech. He co-invented the NovoGen MMX bioprinter platform and grew Organovo through early investments and pharma corporate partnerships. Mr. Murph
Keith Murphy — No Patient Left Behind 0 Skip to Content About Us What We Believe Who We Are Our Team Advisory Councils Life Science Builders 2025 Impact Report Policy NPLB Policy Priorities Value of Medicines Protect Innovation Fix Insurance Most Favored Nation All Letters Learn Fundamentals Biotech Unveiled Call the Inventors Comics Featured Materials Resource library chat-NPLB Webinar Series: The Fine Print Get Involved NPLB Fellowship MA Innovation Storytelling Challenge MA Paradox Patient Stories Become a First Responder Community Quests News Press releases Media Blog Search Donate O … als Resource library chat-NPLB Webinar Series: The Fine Print Get Involved NPLB Fellowship MA Innovation Storytelling Challenge MA Paradox Patient Stories Become a First Responder Community Quests News Press releases Media Blog Search Donate Open Menu Close Menu Folder: About Us Back What We Believe Who We Are Our Team Advisory Councils Life Science Builders 2025 Impact Report Folder: Policy Back NPLB Policy Priorities Value of Medicines Protect Innovation Fix Insurance Most … library chat-NPLB Webinar Series: The Fine Print Folder: Get Involved Back NPLB Fellowship MA Innovation Storytelling Challenge MA Paradox Patient Stories Become a First Responder Community Quests Folder: News Back Press releases Media Blog Search Donate Our Team Keith Murphy CO-CHAIR, ADVISORY BOARD CEO and Founder, Viscient Biosciences Keith Murphy is a scientist, inventor, and entrepreneur who has focused on advancing breakthrough medical technologies. He studied chemical
Keith Murphy - Organovo, Inc. Search About Our Story Who We Are Leadership Team Board of Directors Pipeline Overview Publications News & Events Media Coverage Careers Contact Search for: Keith Murphy Corporate Headquarters 11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121 Tel: (858) 224-1000 Directions Find Us On --> YouTube --> LinkedIn BOD , Management Keith Murphy Keith Murphy is currently CEO and Chairman of Viscient Bio, Inc., and a serial entrepreneur and investor in biotech. Prior to co-founding Viscient Biosciences, Mr. Murphy founded Organovo Inc., in 2007 and led all co
Viscient Bio - HQ | The Org Platform Enrich Pricing Log in Sign up Viscient Bio Offices HQ Unverified HQ 8 people · 0 jobs Viscient Bio's headquarters in San Diego, CA, United States Office location People ( 8 ) Jeffrey N. Miner Founder & CSO David A. Brenner Scientific Advisor Rohit Loomba Scientific Advisor LF Lisa Profeta, FMP Associate Director Of Facility Operations HA Haylee Aidnik, HTL (ASCP) Scientist Ii, Histology Mehrsa Mehrabi, Ph.D. Senior Scientist Payton Olson Senior Research Associate RD Rachel Dudum Scientist II Jobs ( 0 ) No jobs in this office Other offices View al
Viscient Bio Inc | Valuation, Funding Rounds & Stock Price | Caplight NEW Caplight raises a $16M Series A, led by BlackRock and Fin Capital → Products Solutions Resources Log in Book a demo Companies Viscient Bio Inc Viscient Bio Inc Private San Diego, California Healthcare & Life Sciences https://viscientbiosciences.com Last Round Convertible Debt Sep 15, 2021 Total Funding Raised $1M Company Overview Viscient Bio Inc is a biotechnology company that develops novel therapies for liver diseases using proprietary 3D human tissue models. Sector Healthcare & Life Sciences Verticals Dru … ds SternAegis Ventures Convertible Debt Thynk Capital Convertible Debt Harmonix Fund Convertible Debt Methuselah Foundation Convertible Debt View all Investors Viscient Bio Inc Filings SEC and related filings with document metadata. Typed Date Amount Offered Amount Sold Filling Pages Download Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation Mock Valuation Sign Up to view Mock Valuation Sign Up to view Mock Valuation S
Jeffrey N. Miner - Founder & CSO at Viscient Bio | The Org Platform Enrich Pricing Log in Sign up Viscient Bio Jeffrey N. Miner Unverified Jeffrey N. Miner Founder & CSO Contact Prior to founding Viscient, Dr. Miner held research leadership positions at Ardea Biosciences, a member of the Astrazeneca group, and Ligand Pharmaceuticals. His responsibilities at Ardea covered the Biology program as it relates to the discovery, preclinical, translational, and clinical development. He was Head of Molecular and Cellular Biology at Ligand Pharmaceuticals. He is a Faculty Advisor and Molecular … work was conducted in Virology at Oregon State University with a post-doctoral fellowship at the University of California San Francisco in glucocorticoid gene regulation. He has drug discovery experience in the Inflammation, Oncology, Endocrine, and Cardiovascular drug discovery therapeutic areas and his work has led to or enhanced the development of multiple marketed compounds. His target areas of expertise include Nuclear Receptors, Kinases, and Transporters. He has publis
Trailblazing work with 3D Human Liver Models Yields Accurate MASH (formerly NASH) Phenotype Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos … 3D human cellular models with high clinical relevance, and in demonstrating the application of these models to impact drug development at every stage. About Viscient Biosciences Viscient Biosciences is an early-stage biotechnology company that is developing novel therapies for MASH and other liver diseases. Its lead compound, built to a novel target discovered in proprietary 3D models of human liver disease, is expected to enter the clinic in the next 12 months.&n … 3D human cellular models with high clinical relevance, and in demonstrating the application of these models to impact drug development at every stage. About Viscient Biosciences Viscient Biosciences is an early-stage biotechnology company that is developing novel therapies for MASH and other liver diseases. Its lead compound, built to a novel target discovered in proprietary 3D models of human liver disease, is expected to enter the clinic in the next 12 months.&n … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Viscient Biosciences LLC:Company Profile & Technical Research,Competitor Monitor,Market Trends - Discovery | PatSnap Log In Free Trial Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka! Start Your Search Viscient Biosciences LLC Holding Company Startup Follow View Corporate Tree Create Alert Overview Patent Funding Investment Acquisition Member Expert Financial News Basic Info Headquarter California, United States Founded Year 2017 Employees < 10 Social Media http://www.viscientbiosciences.com Viscient Biosciences is a company that provides Drug an … ee Trial Now Download Innovation Matrix visualizing technology portfolio of hot application areas and blank areas for Viscient Biosciences Sign up to view the full data Free Trial Now Download Subsidiary Lists Subsidiaries with patent applications for Viscient Biosciences Sign up to view the full data Free Trial Now Download Viscient Biosciences Frequently Asked Questions What technical fields has Viscient Biosciences researched? Viscient Biosciences has researched the techni
Influencer Interview: Dr. Jeffrey Miner, Viscient Biosciences Blog All Blogs Guides Expert’s Corner Influencer Interviews Events Courses Directory Podcast More FAQ Career Networking ? Live Facebook Group Meetup Media Store About Pitch3D Login Register Blog Events Courses Directory Podcast More All Blogs Guides Expert’s Corner Influencer Interviews FAQ Career Networking Media Store About Pitch3D ? Live Facebook Group Meetup Home Blog Influencer Interviews Interview: Dr. Jeffrey Miner, Founder and Chief Scientific Officer for Viscient Biosciences Interview: Dr. Jeffrey Miner, Founder … work was conducted in virology at Oregon State University with a post-doctoral fellowship at the University of California San Francisco in glucocorticoid gene regulation. He has drug discovery experience in the Inflammation, Oncology, Endocrine and Cardiovascular drug discovery therapeutic areas and his work has led to or enhanced the development of multiple marketed compounds. His target expertise includes Nuclear Receptors, Kinases, and Transporters. He has published … cal translation and complete disease modeling. Solutions: The application and iteration of 3D models, but it will take a lot of work and the climbing of a steep learning curve that we’re just starting to ascend. Jenny: What advice would you give to a smart driven college student in the “real world”? What bad advice you heard should they ignore? Jeff: Good Advice: Ask questions and listen to the answers, then ask another question based on that answer. B
Viscient Bio Proposes Organovo Merger to Tackle NASH and Go Beyond - ManagedLab Services Skip to content Twitter Facebook LinkedIn +1-858-605-7058 Customer Portal Search for: Why ManagedLab? Our Philosophy The Backstory Why Choose ManagedLab? Case Studies Large Biotech Global Pharma Vendor Managed Inventory Scaling Operations Services Vendor Managed Inventory Lab Support Project Management / Lab Moves IT Services Life Sciences Insight Contact Us Careers Viscient Bio Proposes Organovo Merger to Tackle NASH and Go Beyond Posted by ManagedLab | 2019-10-02T08:13:59-07:00 October 2nd, 2019 | [ Upda … tup also based in San Diego, announced Wednesday that it has submitted a merger proposal to the Organovo (NASDAQ: ONVO ) board of directors. The two companies are well-acquainted. They’ve been working together on potential treatments for the fatty liver disease nonalcoholic … Read more » Reprints | Share: UNDERWRITERS AND PARTNERS &nb … Generation Liver, CNS Gene Therapies SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D Archives May 2023 October 2020 September 2020 August 2020 July 2020 June 2020 May 2020 April 2020 March 2020 February 2020 January 2020 December 2019 November 2019 October 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March 2019 February 2019 ManagedLab Services We're leading the North American life science industry in lab support solutions for c
Viscient Biosciences Will Bioprint 3D Lung Tissue to Aid Pandemic Research, and Viscient Founder Calls for Pause in Organovo Merger Attempt Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overvi … gets can be found using 3D bioprinting technology. We now are moving quickly to apply the same technology to create 3D human lung tissue to test potential COVID-19 therapies to accelerate development." Viscient, or a sister company to be funded and launched shortly using the same technology, will now use 3D bioprinting technology to create lung tissue to support viral infectivity research and search for an effective therapy against SARS-CoV-2, the novel coronavirus which caus … ves. In October 2019 , Viscient Biosciences announced that it had made a merger proposal for Organovo. In November 2019 , Organovo announced that it had reached a definitive merger agreement with another company, Tarveda. As a stockholder of Organovo, Mr. Murphy has publicly opposed the Tarveda merger. Organovo called a special meeting of stockholders, to be held on March 26, 2020 , to hold a vote on matters including the approval of measures needed to complete the merger wit … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Viscient Biosciences | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Viscient Biosciences Viscient Biosciences is a biotechnology company focused on utilizing 3D tissue technology to revolutionize drug development and disease modeling. They develop advanced human tissue models, such as liver models that mimic fatty liver disease, to replace outdated animal testing methods. The company's innovative approach aims to improve the accuracy and efficiency of drug discovery and disease research. Industries biotechnology healt
Organovo's Keith Murphy Back as Executive Chairman - 3DPrint.com | Additive Manufacturing Business Site Sponsor: Log In | Register Data & Research PRO Content Advertise Instant 3D Printing Quote Search --> Site Sponsor: News View All News Data & Analysis --> Bioprinting, Medical and Dental 3D Software 3D Scanning Aerospace Education Metals Materials Editorials/Opinions Exclusive Interviews Podcast 3D Printing News Briefs, June 27, 2026: Nanoscale 3D Printing, Defense Readiness, & More US Army Awards Continuous Composites 3D Printed Missile Component Contract Why Qualification Is Beco … ng the Next Frontier for AM in Energy About / Team Advertise Newsletter Contact/Submit Search Data & Research PRO Content Advertise Instant 3D Printing Quote Log In Register Organovo’s Keith Murphy Back as Executive Chairman September 24, 2020 by Vanesa Listek 3D Printing Bioprinting Business Featured Stories Share this Article --> Founder and former CEO of Organovo , Keith Murphy, is back as the company’s newly appointed Executive Chairman of the Board. The news comes … for life sciences and technology companies; David Gobel, CEO of the Methuselah Fund , and Douglas Jay Cohen, CEO of medical device company IR Medtek. Additionally, Organovo will have a new leadership team, Viscient co-founder Jeffrey N. Miner will be the new Chief Scientific Officer (CSO); Chris Heberlig has taken on the role as President and Chief Financial Officer (CFO), and Thomas Jurgensen is the new General Counsel for Organovo. While the existing executive officers, in
Viscient Biosciences Will Bioprint 3D Lung Tissue to Aid Pandemic Research, and Viscient Founder Calls for Pause in Organovo Merger Attempt - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufactu … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Biotech Beach Viscient Biosciences Will Bioprint 3D Lung Tissue to Aid Pandemic Research, and Viscient Founder Calls for Pause in Organovo Merger Attempt March 31, 2020 | 6 min read Twitter LinkedIn Facebook Email Print Keith Murphy, founder and Chief Executive Officer of Viscient Biosciences (“Viscient”), today is call … gets can be found using 3D bioprinting technology. We now are moving quickly to apply the same technology to create 3D human lung tissue to test potential COVID-19 therapies to accelerate development." Viscient, or a sister company to be funded and launched shortly using the same technology, will now use 3D bioprinting technology to create lung tissue to support viral infectivity research and search for an effective therapy against SARS-CoV-2, the novel coronavirus which caus … ves. In October 2019 , Viscient Biosciences announced that it had made a merger proposal for Organovo. In November 2019 , Organovo announced that it had reached a definitive merger agreement with another company, Tarveda. As a stockholder of Organovo, Mr. Murphy has publicly opposed the Tarveda merger. Organovo called a special meeting of stockholders, to be held on March 26, 2020 , to hold a vote on matters including the approval of measures needed to complete the merger wit … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin